Dare Bioscience, Inc. (DARE) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Dare Bioscience, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.054 Hello and welcome to the Data Bioscience second quarter 2026 00:00:05.054 -- 00:00:08.136 corporate update conference call and webcast. 00:00:08.136 -- 00:00:13.018 As a brief reminder, all participants are in a listen-only mode. 00:00:13.018 -- 00:00:16.560 Following the presentation, there will be a question and answer session. 00:00:16.560 -- 00:00:21.303 Note that this webcast is being recorded at the company's request and a replay will be 00:00:21.303 -- 00:00:25.865 made available on the company's website following the end of the event. 00:00:25.865 -- 00:00:30.928 Joining us today from Data Bioscience are Sabrina Martucci Johnson, President and Chief 00:00:30.928 -- 00:00:35.251 Executive Officer, and MarDee Haring-Layton, Chief Accounting Officer. 00:00:35.251 -- 00:00:38.912 Ms. Haring-Layton, please proceed. 00:00:39.594 -- 00:00:44.097 Good afternoon and welcome. Today we will review our financial results, provide updates 00:00:44.097 -- 00:00:48.560 on our commercial products and clinical pipeline, and discuss the continued execution 00:00:48.560 -- 00:00:53.157 of our expanded business strategy. That strategy includes a dual path approach. 00:00:53.157 -- 00:00:58.341 commercializing proprietary formulations through 503 compounding while pursuing FDA 00:00:58.341 -- 00:01:02.624 approval and advancing select solutions as branded consumer health products that do not 00:01:02.624 -- 00:01:07.268 require a prescription. In all cases, our goal is to bring innovative women's health 00:01:07.268 -- 00:01:11.030 solutions to market as efficiently and quickly as possible. 00:01:11.030 -- 00:01:14.573 I would like to remind you that today's discussion will include forward-looking statements 00:01:14.573 -- 00:01:18.716 within t...